MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/tcrm.s175772

Медицинская библиотека · Therapeutics and clinical risk management · 2018

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.

Niccoli Laura, Nannini Carlotta, Blandizzi Corrado, Mantarro Stefania, Mosca Marta, Di Munno Ombretta, Goletti Delia, Benucci Maurizio, Gobbi Francesca Li, Cassarà Emanuele, Kaloudi Olga, Cantini Fabrizio

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on bone mass and sexual sphere, and relationship between RA and periodontal disease (PD).

METHODS

An overview of existing evidence was undertaken by an expert panel on behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO). Data were extracted from controlled trials, national registries, national health care databases, post-marketing surveys, and, when required by the paucity of controlled studies, from open-label clinical series. Anti-tumor necrosis factor (anti-TNF) and non-anti-TNF-targeted biologics approved for RA were investigated.

RESULTS

ADAb formation is chiefly associated with anti-TNFs, and it is reduced by combination therapy with methotrexate. To date, ADAb titration is not advisable for clinical practice, and, in case of anti-TNF secondary failure, a non-anti-TNF biologic is indicated. LLS is observed in anti-TNF receivers and, in most cases, resolves without anti-TNF withdrawal. A non-anti-TNF biologic is advisable in patients experiencing LLS. Non-anti-TNFs demonstrated a low or absent infection risk and are preferable in patients with comorbidities. Due to their positive effects on bone mass, anti-TNFs are indicated in women at osteoporosis risk, whereas non-anti-TNF have been poorly investigated. The emerging evidence of the relationship between RA and PD and the effects on anti-TNF efficacy should lead clinicians to consider the periodontal status in RA patients. Anti-TNFs may exert a positive effect on fertility and sexuality, and clinicians should explore these aspects in RA patients.

CONCLUSION

The optimization of biologic therapies by taking into proper account the above issues would improve patient outcomes.

Для цитирования: Niccoli Laura, Nannini Carlotta, Blandizzi Corrado, Mantarro Stefania, Mosca Marta, Di Munno Ombretta, Goletti Delia, Benucci Maurizio, Gobbi Francesca Li, Cassarà Emanuele, Kaloudi Olga, Cantini Fabrizio. Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.. Therapeutics and clinical risk management. 2018. DOI: 10.2147/tcrm.s175772.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.